A druggable addiction to de novo pyrimidine biosynthesis in diffuse midline glioma
S. PAL, J. P. Kaplan, H. Nguyen, S. A. Stopka, M. R. Savani, M. S. Regan, Q.-D. Nguyen, K. L. Jones, L. A. Moreau, J. Peng, M. G. Dipiazza, A. Perciaccante, X. Zhu, B. Hunsel, K. X. Liu, , D. Haas-Kogan
This paper identifies a druggable metabolic vulnerability in diffuse midline glioma through a CRISPR screen, showing that inhibition of DHODH reduces pyrimidine biosynthesis and extends survival in mouse models.
bioRxiv · Nov 30, 2021Cancer Biology